Investors who suffered significant losses from POMDoctor Ltd. should consider participating in a class action lawsuit filed by Robbins LLP. The lawsuit represents all shareholders who purchased or acquired POMDoctor securities between October 9, 2025, and December 11, 2025.
POMDoctor, listed on NASDAQ as POM, claims to be “a leading online medical services platform for chronic diseases in China.” The class action arises amid allegations of a fraudulent scheme that inflated the company’s stock price prior to its initial public offering (IPO).
Allegations of Fraudulent Activity
According to the complaint, POMDoctor’s share price increased dramatically from its IPO price of $4.00 to an all-time high of $6.09 in the weeks leading up to December 10, 2025. This surge occurred without any fundamental news from the company, raising red flags. Following this spike, the stock price crashed by approximately 91% on the IPO date, falling to just $0.50. Since then, the share price has continued to decline, currently hovering around $0.40.
The lawsuit claims that POMDoctor was involved in a “pump-and-dump” scheme. Investigations revealed that the company allegedly used social media to spread misinformation, with impersonators posing as financial advisors to promote the stock. These false endorsements led to a buying frenzy among retail investors.
Key allegations include a failure by the defendants to disclose critical information to investors, such as: (i) POMDoctor’s involvement in a stock promotion scheme driven by misinformation, (ii) the use of offshore or nominee accounts by insiders to facilitate the sale of shares during artificially inflated prices, and (iii) omissions in public statements regarding the false rumors and trading activities impacting the stock price.
Next Steps for Shareholders
Shareholders interested in participating in the class action against POMDoctor Ltd. must submit their lead plaintiff papers to the court by April 7, 2026. The lead plaintiff acts on behalf of other class members in the litigation process. Importantly, investors do not need to take any action to remain part of the class and can still be eligible for recovery if they choose to remain absent.
For more information on how to proceed, investors can contact attorney Aaron Dumas, Jr. at Robbins LLP, call (800) 350-6003, or visit their website. All representation is offered on a contingency fee basis, meaning shareholders incur no costs unless the case is successful.
Robbins LLP has established itself as a leader in shareholder rights litigation since 2002, focusing on helping investors recover losses and hold company executives accountable for misconduct. To receive updates on the class action or alerts regarding corporate wrongdoing, interested parties can sign up for Stock Watch.
Attorney advertising is noted, and past results do not guarantee future outcomes.
